mazdutide
Selected indexed studies
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. (N Engl J Med, 2025) [PMID:40421736]
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. (Nature, 2026) [PMID:41407860]
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. (Diabetes Care, 2024) [PMID:37943529]
_Worker-drafted node — pending editorial review._
Connections
mazdutide is a side effect of
Sources
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. (2026) pubmed
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. (2025) pubmed
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. (2024) pubmed
- Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis. (2025) pubmed
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. (2023) pubmed
- Mazdutide: First Approval. (2025) pubmed
- Mazdutide versus placebo in Chinese adults with type 2 diabetes. (2026) pubmed
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials. (2024) pubmed
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. (2022) pubmed
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. (2024) pubmed